N4 Pharma Plc (AIM:N4P)

Market Cap	4.16M
Revenue (ttm)	7.28K
Net Income (ttm)	-1.06M
Shares Out	832.28M
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,646,182
Average Volume	1,194,179
Open	0.4220
Previous Close	0.4500
Day's Range	0.4000 - 0.5000
52-Week Range	0.3500 - 0.8000
Beta	0.63
RSI	74.45
Earnings Date	Sep 17, 2025

About N4 Pharma

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-cl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1979
• Employees: 4
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: N4P

Financial Performance

In 2024, N4 Pharma's revenue was 7,282, an increase of 272.86% compared to the previous year's 1,953. Losses were -1.06 million, -16.60% less than in 2023.